Saudi Arabia Consensus Guidance for the Diagnosis and Management of Adults with Inflammatory Bowel Disease

Overview

Journal Saudi J Gastroenterol

Specialty Gastroenterology

Date 2022 Nov 22

PMID 36412460

Authors

Mahmoud H Mosli

Hajer Y Almudaiheem

Turki AlAmeel

Shakir A Bakkari

Othman R Alharbi

Khalidah A Alenzi

Amr M Khardaly

Maha A AlMolaiki

Bedor A Al-Omari

Rayan G Albarakati

Ahmed H Al-Jedai

Omar I Saadah

Majid A Almadi

Badr Al-Bawardy

Affiliations

Soon will be listed here.

Abstract

Optimal management of inflammatory bowel disease (IBD) relies on a clear understanding and tailoring evidence-based interventions by clinicians in partnership with patients. This article provides concise guidelines for the management of IBD in adults, based on the most up-to-date information at the time of writing and will be regularly updated. These guidelines were developed by the Saudi Ministry of Health in collaboration with the Saudi Gastroenterology Association and the Saudi Society of Clinical Pharmacy. After an extensive literature review, 78 evidence-and expert opinion-based recommendations for diagnosing and treating ulcerative colitis and Crohn's disease in adults were proposed and further refined by a voting process. The consensus guidelines include the finally agreed on statements with their level of evidence covering different aspects of IBD diagnosis and treatment.

Citing Articles

Budget impact analysis of subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in Saudi Arabia: Analysis from payer perspective.

Alkhatib N, Almutairi A, Almadi M, Halloush S, Al-Ruthia Y, Rashdan O PLoS One. 2024; 19(11):e0312603.

PMID: 39531466 PMC: 11556681. DOI: 10.1371/journal.pone.0312603.

The effectiveness of vedolizumab in advanced therapy-experienced ulcerative colitis patients: Real world data from the Inflammatory Bowel Disease of the Middle East (IBD-ME) Registry group.

Azzam N, Alharbi O, Altuwaijri M, AlRuthia Y, Alfarhan H, Alshankiti S Saudi J Gastroenterol. 2024; 31(1):34-40.

PMID: 39291466 PMC: 11804962. DOI: 10.4103/sjg.sjg_249_24.

Short term effectiveness of ustekinumab versus vedolizumab in Crohn's disease after failure of anti-TNF agents: An observational comparative study design with a Bayesian analysis.

Alamer A, Al Lehaibi L, Alomar M, Aldhuwayan F, Alshouish S, Al-Ali A Saudi J Gastroenterol. 2024; 30(5):324-334.

PMID: 39157885 PMC: 11534192. DOI: 10.4103/sjg.sjg_101_24.

Inflammatory bowel disease training assessment of gastroenterology fellows in Saudi Arabia.

AlDhneem H, AlMutairdi A, Attamimi M, Mosli M, AlAmeel T, Al-Bawardy B Saudi J Gastroenterol. 2024; 30(4):260-265.

PMID: 38841910 PMC: 11379256. DOI: 10.4103/sjg.sjg_19_24.

Epstein-Barr virus seroprevalence among inflammatory bowel disease patients in Saudi Arabia.

Al-Bawardy B, Alfadley A, Almousallam M, Alshathri S, Aboueissa M, Alsulaiman A Saudi J Gastroenterol. 2024; 30(3):168-172.

PMID: 38358251 PMC: 11198918. DOI: 10.4103/sjg.sjg_380_23.

References

Shimoyama T, Yamamoto T, Umegae S, Matsumoto K . Faecal biomarkers for screening small bowel inflammation in patients with Crohn's disease: a prospective study. Therap Adv Gastroenterol. 2017; 10(8):577-587. PMC: 5557189. DOI: 10.1177/1756283X17717683. View

Regueiro M . The role of endoscopy in the evaluation of fistulizing Crohn's disease. Gastrointest Endosc Clin N Am. 2002; 12(3):621-33. DOI: 10.1016/s1052-5157(02)00013-2. View

Burri E, Maillard M, Schoepfer A, Seibold F, Van Assche G, Riviere P . Treatment Algorithm for Mild and Moderate-to-Severe Ulcerative Colitis: An Update. Digestion. 2020; 101 Suppl 1:2-15. DOI: 10.1159/000504092. View

Satsangi J, Silverberg M, Vermeire S, Colombel J . The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006; 55(6):749-53. PMC: 1856208. DOI: 10.1136/gut.2005.082909. View

Liu W, Liu J, Xiao W, Luo G . A Diagnostic Accuracy Meta-analysis of CT and MRI for the Evaluation of Small Bowel Crohn Disease. Acad Radiol. 2017; 24(10):1216-1225. DOI: 10.1016/j.acra.2017.04.013. View

Cummings J, Keshav S, Travis S . Medical management of Crohn's disease. BMJ. 2008; 336(7652):1062-6. PMC: 2376027. DOI: 10.1136/bmj.39547.603218.AE. View

Long M, Sands B . What Is the Role of the Inflammatory Bowel Disease Panel in Diagnosis and Treatment?. Clin Gastroenterol Hepatol. 2018; 16(5):618-620. DOI: 10.1016/j.cgh.2018.02.010. View

Samaan M, Birdi S, Morales M, Honap S, Tamilarasan A, Cunningham G . Effectiveness of vedolizumab dose intensification to achieve inflammatory bowel disease control in cases of suboptimal response. Frontline Gastroenterol. 2020; 11(3):188-193. PMC: 7223295. DOI: 10.1136/flgastro-2019-101259. View

Ford A, Achkar J, Khan K, Kane S, Talley N, Marshall J . Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2011; 106(4):601-16. DOI: 10.1038/ajg.2011.67. View

10.

Danese S, Siegel C, Peyrin-Biroulet L . Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis. Aliment Pharmacol Ther. 2014; 39(10):1095-103. DOI: 10.1111/apt.12712. View

11.

Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J . Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. Am J Gastroenterol. 2018; 113(9):1345. PMC: 6445254. DOI: 10.1038/s41395-018-0162-0. View

12.

Fine S, Papamichael K, Cheifetz A . Etiology and Management of Lack or Loss of Response to Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2020; 15(12):656-665. PMC: 6935028. View

13.

Al-Ghamdi A, Al-Mofleh I, Al-Rashed R, Al-Amri S, Aljebreen A, Isnani A . Epidemiology and outcome of Crohn's disease in a teaching hospital in Riyadh. World J Gastroenterol. 2004; 10(9):1341-4. PMC: 4622779. DOI: 10.3748/wjg.v10.i9.1341. View

14.

Sprakes M, Hamlin P, Warren L, Greer D, Ford A . Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience. J Crohns Colitis. 2011; 5(4):324-31. DOI: 10.1016/j.crohns.2011.02.007. View

15.

van Rheenen P, Aloi M, Assa A, Bronsky J, Escher J, Fagerberg U . The Medical Management of Paediatric Crohn's Disease: an ECCO-ESPGHAN Guideline Update. J Crohns Colitis. 2020; . DOI: 10.1093/ecco-jcc/jjaa161. View

16.

Lee A, Caldera F . Is Vedolizumab Truly Gut Selective? It May Not Affect the Immunogenicity of Vaccines in Patients With Inflammatory Bowel Disease. Crohns Colitis 360. 2023; 2(4):otaa086. PMC: 9802035. DOI: 10.1093/crocol/otaa086. View

17.

Schoepfer A, Beglinger C, Straumann A, Trummler M, Renzulli P, Seibold F . Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis. 2009; 15(12):1851-8. DOI: 10.1002/ibd.20986. View

18.

Perry C, Fischer K, Elmoursi A, Kern C, Currier A, Kudaravalli P . Vedolizumab Dose Escalation Improves Therapeutic Response in a Subset of Patients with Ulcerative Colitis. Dig Dis Sci. 2020; 66(6):2051-2058. DOI: 10.1007/s10620-020-06486-x. View

19.

Timmer A, Patton P, Chande N, McDonald J, MacDonald J . Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016; (5):CD000478. PMC: 7034525. DOI: 10.1002/14651858.CD000478.pub4. View

20.

DHaens G, Vermeire S, Lambrecht G, Baert F, Bossuyt P, Pariente B . Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease. Gastroenterology. 2018; 154(5):1343-1351.e1. DOI: 10.1053/j.gastro.2018.01.004. View